Nabriva Therapeutics plc
DelistedCIK 1641640fmd_1A16DDH3GWEAVZF7XEHNY7S1T0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Jun 30, 2023, 35 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 6 | 5 | 10 | 9 | 5 | 29 | 37 |
| Cost of revenue | – | – | – | – | – | 0 | 1 | 13 | 29 |
| Gross profit | – | – | – | – | – | 9 | 4 | 16 | 8 |
| Research and development | – | 24 | 48 | 50 | 82 | 26 | 15 | 13 | 14 |
| Selling, general and administrative | – | – | – | 29 | 42 | 62 | 55 | 52 | 45 |
| Total operating expenses | 13 | 32 | 62 | 79 | 124 | – | – | – | – |
| Operating income | (11) | (28) | (55) | (74) | (114) | (79) | (66) | (49) | (55) |
| Interest expense | 3 | 22 | 0 | 0 | 0 | 3 | 2 | 1 | 1 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – |
| Other non-operating income (expense) | (1) | 2 | (1) | 0 | (0) | 0 | 1 | 0 | 1 |
| Income before taxes | (14) | (47) | (56) | (73) | (115) | (83) | (69) | (49) | (56) |
| Income tax expense | 0 | (0) | (1) | 1 | 0 | 0 | 0 | 0 | 2 |
| Net income from continuing operations | (14) | (47) | (55) | (74) | (115) | (83) | (69) | (49) | (57) |
| Net income | (14) | (47) | (55) | (74) | (115) | (83) | (69) | (49) | (57) |
| Net income to common shareholders | (14) | (51) | (55) | (74) | – | – | – | – | – |